Spolaore et al., 2014 - Google Patents

Site-specific derivatization of avidin using microbial transglutaminase

Spolaore et al., 2014

Document ID
17146393317119639695
Author
Spolaore B
Damiano N
Raboni S
Fontana A
Publication year
Publication venue
Bioconjugate Chemistry

External Links

Snippet

Avidin conjugates have several important applications in biotechnology and medicine. In this work, we investigated the possibility to produce site-specific derivatives of avidin using microbial transglutaminase (TGase). TGase allows the modification of proteins at the level of …
Continue reading at pubs.acs.org (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment

Similar Documents

Publication Publication Date Title
Matos et al. Chemo-and regioselective lysine modification on native proteins
Kuan et al. Functional protein nanostructures: a chemical toolbox
Chen et al. Genetically encoding an electrophilic amino acid for protein stapling and covalent binding to native receptors
Munasinghe et al. Molecular insight into the protein–polymer interactions in N-terminal PEGylated bovine serum albumin
Hussain et al. Toward homogenous antibody drug conjugates using enzyme-based conjugation approaches
Dennler et al. Microbial Transglutaminase and c‐myc‐Tag: A Strong Couple for the Functionalization of Antibody‐Like Protein Scaffolds from Discovery Platforms
CN107614514A (en) Modified using the antibody specificity of IgG binding peptides
EP3706804B1 (en) Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
Lui et al. Targeting the tumor vasculature with engineered cystine-knot miniproteins
Lee et al. Dual site-specific labeling of an antibody fragment through sortase A and π-clamp conjugation
Spolaore et al. Site-specific derivatization of avidin using microbial transglutaminase
Yu et al. Efficient labeling of native human IgG by proximity-based sortase-mediated isopeptide ligation
Yu et al. Site-specific albumin-selective ligation to human serum albumin under physiological conditions
Agrawalla et al. Chemoselective dual labeling of native and recombinant proteins
Takahara et al. Extending the half-life of a protein in vivo by enzymatic labeling with amphiphilic lipopeptides
Zheng et al. Site-specific PEGylation of anti-Mesothelin recombinant immunotoxins increases half-life and antitumor activity
Jhan et al. Dimethyl labeling coupled with mass spectrometry for topographical characterization of primary amines on monoclonal antibodies
Kehrein et al. Molecular dynamics simulations for rationalizing polymer bioconjugation strategies: challenges, recent developments, and future opportunities
Ohno et al. Selective pH-Responsive Conjugation between a Pair of De Novo Discovered Peptides
Hashad et al. Chemoselective methionine labelling of recombinant trastuzumab shows high in vitro and in vivo tumour targeting
Holm et al. Electrophilic affibodies forming covalent bonds to protein targets
Wang et al. Reverse binding mode of phosphotyrosine peptides with SH2 protein
Keeble et al. Design and Evolution of Enhanced Peptide–Peptide Ligation for Modular Transglutaminase Assembly
US11428687B2 (en) Molecular sensors
Hung et al. Synthesis and systematic study on the effect of different PEG units on stability of PEGylated, integrin-αvβ6-specific A20FMDV2 analogues in rat serum and human plasma